Company news
Caredx, Inc. (NASDAQ:CDNA) news
Every Caredx, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CareDx Announces Second Quarter 2026 Financial Results
July 30, 2026
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
July 16, 2026
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
July 16, 2026
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
July 1, 2026
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
June 30, 2026
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
June 18, 2026
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
June 16, 2026
CareDx Announces Dismissal of 2021 Qui Tam Suit
May 11, 2026
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
April 28, 2026
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung T...
April 21, 2026
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
April 20, 2026
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary...
April 15, 2026
CareDx to Report First Quarter 2026 Financial Results on April 28, 2026
April 14, 2026
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid ...
March 5, 2026
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
February 24, 2026
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
February 18, 2026
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
February 12, 2026
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 10, 2026
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
February 3, 2026
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 27, 2026
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 27, 2026
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
January 7, 2026
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 26, 2025
CareDx Provides Notice of Proposed Derivative Settlement
December 18, 2025
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplanta...
November 24, 2025
CareDx to Participate in Upcoming Investor Conferences
November 10, 2025
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
November 6, 2025
CareDx Announces Third Quarter 2025 Financial Results
November 4, 2025
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
October 27, 2025
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the A...
October 23, 2025
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
October 22, 2025
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
October 21, 2025
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & ...
October 6, 2025
CareDx Issues Comment Letter on Draft LCD Policy
September 2, 2025
CareDx to Participate in Wells Fargo Healthcare Conference
August 21, 2025
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors
August 12, 2025
CareDx Announces Second Quarter 2025 Financial Results
August 6, 2025
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
August 6, 2025
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
August 6, 2025
CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 ...
July 31, 2025
CareDx to Report Second Quarter 2025 Financial Results
July 23, 2025
CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
July 18, 2025
CareDx Announces Repurchase of 5% of Outstanding Shares
June 3, 2025
CareDx Reports First Quarter 2025 Results
April 30, 2025
CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting
April 29, 2025
CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transp...
April 24, 2025
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 21, 2025
CareDx to Report First Quarter 2025 Financial Results
April 8, 2025